Key result
Sarcopenia in CHF is linked to ~39% higher circulating miR-1-3p expression.
Why the study?
Sarcopenia is an important clinical finding in chronic heart failure, but efforts to identify a reliable biomarker predicting muscular and functional decline had been unsuccessful.
Does circulating miR-1-3p predict sarcopenia status in older adults with chronic heart failure?
Cross-Sectional (n=80)
No
Does circulating miR-1-3p predict sarcopenia status in older adults with chronic heart failure?
Absolute Event Rate: 1.69% vs 1.22%
p-value: p=<0.05
Circulating miR-1-3p levels are significantly elevated in chronic heart failure patients with sarcopenia and correlate with muscle mass and strength, suggesting its potential as a diagnostic biomarker.
Elevated miR-1-3p was associated with sarcopenia in chronic HF; leaves open its value as a predictive biomarker.
Background: While sarcopenia is an important clinical finding in individuals diagnosed with chronic heart failure (CHF), efforts to identify a reliable biomarker capable of predicting the overall muscular and functional decline in CHF patients have been unsuccessful to date. Objectives: The objectives of this study were to study the diagnostic utility of MicroRNA (miRNA)-1-3p as a predictor of sarcopenia status in individuals diagnosed with CHF. Methods: In total, 80 individuals with heart failure exhibiting a left ventricular ejection fraction < 50% were enrolled in this study. All patients were analyzed to assess miR-1-3p expression levels, with body composition being evaluated through dual-energy X-ray absorptiometry and sarcopenia being defined based on the sum of appendicular lean muscle mass (ALM) divided by height in meters squared and handgrip strength (HGS). In addition, the activation of the Akt/mTOR signaling pathway was evaluated in these individuals. Results: In total, 40 of the enrolled patients (50%) exhibited sarcopenia. Sarcopenic patients presented with increased miR-1-3p expression levels as compared to non-sarcopenic individuals (1.69 ± 0.132 vs. 1.22 ± 0.106; p < 0.05). With respect to sarcopenic indices, appendicular skeletal mass index was most strongly correlated with miR-1-3p expression, which was also strongly correlated with HGS. High levels of Akt/mTOR signaling pathway components were expressed in sarcopenic individuals, highlighting a significant relationship between miR-1-3p activity and signaling through this pathway. Moreover, miR-1-3p was identified as a specific marker for sarcopenia in individuals with CHF. Conclusions: These results suggest that circulating miR-1-3p levels are related to Akt/mTOR pathway activation and can offer valuable insight into the overall physical capacity and muscular integrity of CHF patients as a predictor of sarcopenia. (Rev Invest Clin. 2022;74(5):276-83).
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) conducted a cross-sectional in Chronic Heart Failure and Sarcopenia (n=80). Sarcopenia vs. Without sarcopenia was evaluated on miR-1-3p expression levels (p=<0.05). Sarcopenic patients with chronic heart failure exhibited significantly higher circulating miR-1-3p expression levels compared to non-sarcopenic patients (1.69 vs. 1.22; p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: